The Role of CD164 in Metastatic Cancer by Havens, Aaron M. et al.
UNIVERSITY OF MICHIGAN UNDERGRADUATE RESEARCH FORUM20
The Role of CD164 in Metastatic 
Cancer 
Aaron M. Havens
J. Wang, Y-X. Sun, G. Heresi, R.S. Taichman
Mentor:  Russell Taichman
The spread of tumors, a process called
metastasis, is a dreaded complication in the
progression of many cancers. This complication is most
severe when the tumors spread or ‘home’ to the bone,
as they frequently do in breast or prostate cancers.
Blood or hematopoietic cells also ‘home’ to bone during
development and there is now compelling evidence
that the growth factor/chemokine (a growth factor
that attracts cells) stromal-derived factor-1 (SDF-1)
plays a critical major role in the process.  We predicted
that SDF-1 and its receptor CXCR4, as well as genes
activated by SDF-1, may play an essential role in
targeting tumors to the bone marrow.
To investigate this hypothesis, we examined
prostate cancer as a model for a tumor that frequently
metastasizes to bone. Previously, we have
demonstrated that prostate cancer cell lines express
CXCR4, adhere to endothelium, and migrate through
basement membranes in response to SDF-1 [1].  More
recently, we determined that SDF-1 and CXCR4 are
expressed by human prostate cancers in vivo [2]. To
identify genes activated by SDF-1 in prostate cancers
which might facilitate the establishment of bone
metastases, we treated prostate cancers with SDF-1
and examined changes in gene expression at the
mRNA level using gene arrays.  For our investigations,
we treated the metastatic human prostate cancer cell
lines LNCaP and LNCaP C4-2B with SDF-1.
Originally LNCaP cells were isolated from a lymph
node of a patient with widespread bony and lymph
node involvement.  These cells were passaged in mice
until a sub line was identified with increased bone
homing capabilities (LNCaP C4-2B) [3]. The LNCaP
cells and the LNCaP sub line C4-2B cells were
originally obtained from UroCor, Inc (Oklahoma City,
OK).     Several prostate cancer cell lines were used
in our studies.
In order to determine which genes in prostate
cancers are altered by treatment with SDF-1, we
utilized DNA Microarrays, a tool for the fast
monitoring of a large number of genes at once.   With
this technology, we analyzed the expression of over
20,000 genes.  In general, a microarray consists of
gene sequences or fragments of genes called
expressed sequence tags (ESTs). Very small amounts
of hundreds or thousands of these ESTs are arranged
on a single microarray substrate, often glass, usually
by a robotic device. The genetic messenger (RNA or
mRNA) which signals protein production interest is
labeled, purified, and allowed to bind to the microarray.
Later an imaging scanner reads the signal intensity
(degree of hybridization) of a sample at each spot on
the microarray.  The analysis software formulates this
information generated from the imaging scanner and
uses the information to extract, manage and present
the information in a usable fashion.  In the past, we
have only been able to conduct analyses on a few
genes at once.
With the development of microarray
technology, we can now examine thousands of genes
at the same time. In order to perform the microarray
analysis, RNA was collected by standard methods
from SDF-1 stimulated LNCaP and LNCaP C4-2B
cells and compared to RNA collected from cells that
were not treated with SDF-1.  For our analysis, we
used 4 Affymetrix HG-U133A chips that contained
signals for approximately one half of the human
genome, obtained by the University of Michigan
Dental School Microarray Facility. The raw data was
transferred into the statistical software and then
calculated expression values were performed using a
Robust Multi-array Average (RMA).[4]). We chose
this  program to ‘fit’ a model to the data in order to
calculate relative expression values [5].  After the
expression values were calculated, the data was
further analyzed using Significance Analysis of
Microarrays (SAM), a program that calculates various
statistical tests with adjustments for multiple
comparisons using False Discovery Rate (FDR) [6].
The comparison of the SDF-1 (at a physiologic dose
of 200 ng/ml) treated and untreated cells was
straightforward and performed using a t-test that
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Figure 1:  Gel Electrophoresis of CD164 Exon 1-6  This non-quantitative polyacrylamide gel shows the
DNA sequences depicted over the designated exons (coding regions of DNA).  Three types of cDNA are
shown for each set of primers (probes for detecting the presence of the DNA) presented. Data is for
LNCaP C4-2B cells treated with SDF-1(+), or cells that were not treated (-). The human hematopoietic cell
line KG1a was utilized as a positive control.  A molecular weight ladder corresponding to differences in 100
base pairs is shown to the left of each figure.
compares the mean of the expression values for each
gene (at each time).
Initially our analysis revealed that there were
~300 genes in which expression increased in response
to SDF-1. From these, the gene CD164 was identified
as a SDF-1-responsive gene that is potentially involved
in the homing process of prostate cancers to the
marrow.  CD164 is a protein of ~160 kDa initially
identified on very primitive blood cell precursors.
CD164 is known to function as an adhesion receptor
during blood development, facilitating the adhesion of
these early cells to their support cells in the bone
marrow (or stromal cells) [7,8].
To verify the results from the microarray, we
examined several prostate cancer cells for the
expression of CD164 by Reverse Transcriptase –
Polymerase Chain Reaction (RT-PCR). This
technology was first developed in the late 1980’s and
allows one to rapidly assess the presence or absence
of a gene in a given sample of messenger RNA.  We
chose reagents for these analyses that were designed
to cross intron/exon boundaries to ensure that we were
not obtaining false positive signals. The first step in
this technology was to isolate mRNA from the cells
of interest and to then convert the mRNA into a
complementary copy of DNA.   Polymerase Chain
Reaction or PCR was then used to make many copies
of the gene CD164, and we incorporated many
controls into our experiment to control for false signals.
The PCR product was then analyzed in a DNA or
polyacrylamide gel, where the amount of DNA base
pairs can be quantified.    As illustrated in Figure 1,
gel electrophoresis shows that CD164 is expressed
by the bone homing prostate cancer cell line LNCaP
C4-2B, and the major mRNA produced by the tumor
cells is the full length version of the mRNA (unspliced
species). We cloned and sequenced the RT-PCR
product to confirm this result. (Figure 2). The RT-
PCR result provided further validation of the
microarray results.
In order to determine whether prostate cancer
cells actually make the protein coded for by the mRNA
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Figure 2: DNA Sequence Results  DNA sequencing was performed by extracting the DNA from the
gels in figure 1.  Sequencing results along with the matched sequence of the gene CD164 cDNA (AF299341)
in Gene Bank are shown, demonstrating Intron-Exon boundaries. (A.) The cDNA sequenced was C4-2B
SDF-1 + between primers that are targeted for the full length transcript (F164 to B7).  (B.)  The cDNA
sequenced was C4-2B SDF-1 – between the primers that are targeted for the full length transcript (F164 to
B7).
that we detected by microarray and RT-PCR, we
turned to Fluorescence Activated Cytometry (FACs).
This technology allows detection of proteins on the
surface of cells using colored antibodies and lasers.
Here we examined the relative protein expression
levels of CD164 on LNCaP C4-2B cells, PC3 cells
(originally isolated from a vertebral metastasis of a
human prostate cancer patient) or MCF-7 (a breast
cancer cell line) with a commercially available
antibody directed against CD164. For these
investigations, cells were incubated over a three-hour
period in the presence or absence of SDF-1 and
subsequently stained with the antibody to CD164 (or
an antibody control). Thereafter, members of the
University of Michigan Cancer Center Cytometry
Core Facilities examined the cells for the expression
of CD164. The data demonstrates that by three hours
both the LNCaP C4-2B and PC3 prostate cancer cells
increased their expression of CD164 in the presence
of SDF-1 (Figure 3). Surprisingly, the breast cancer
cell line, which also homes to bone, did not alter the
expression of CD164, suggesting that there may be
alternative mechanisms involved in marrow homing
by different tumor types (Figure 3).
Finally, to further verify that prostate cancer
cells express CD164, we measured the expression of
CD164 in human prostate cancer cells and human
lymph node.  An antibody to CD164 that was hooked
to an enzyme was used to stain biopsies of patient
samples. The expression of CD164 was detected by
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Figure 4:  Immunohistochemistry of Prostate Cancer and Lymph Node
Immunohistochemistry was performed on patient samples of both prostate cancer and lymph node cells.  The
samples were stained with an antibody to CD164.  (A, B) Human prostate cancer tissue biopsy demonstrated the
intense brown staining of CD164, indicating the presence of CD164 in human prostate cancer.  (20X) (C.)  Positive
control staining of a human lymph node at 20x magnification.
Figure 3:  Flow Cytometry Analysis for SDF-1 Stimulated PC3 or LNCaP C4-2B Cells  A.)  Flow
cytometry results of PC3 cells treated with SDF-1.  The slight shift of the antibody-stained cells of SDF-1
treatment for 3 hours shows that more PC3 cells were stained during analysis.  B.)  Flow cytometry results
of LNCaP C4-2B cells treated with SDF-1.  The shift of the antibody-stained cells with SDF-1 treatment for
2 hours shows that the expression of CD164 is increased as the levels of SDF-1 are heightened when
compared to the antibody-stained cells with no SDF-1 treatment.  C.)  Flow Cytometry results of MCF-7
cells treated with SDF-1.  Both graphs show an IgG control.
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the ability of the enzyme to break down a substrate
that turns a color – the result in this case is the
presence of a brown stain on the tissue samples (Figure
4). The data demonstrates that CD164 is expressed
by prostate cancer cells in patients and is not merely
related to a culture artifact.
In summary, we have identified CD164 as a
SDF-1 responsive gene in prostate cancers that is a
reasonable candidate for a protein possibly involved
in homing to the bone marrow.  Thus far we have
determined that CD164 mRNA is expressed by
prostate cancer cell lines in relation to SDF-1
treatment.   In addition, we have determined the protein
expression of CD164 through flow cytometry or FACs
analysis of metastatic cancer cell lines.  At this point
we have also found that the gene CD164 is responsive
to heightened levels of SDF-1 and believe that CD164
is a gene responsible for adhesion molecules involved
in prostate cancer homing to the bone marrow. Further
studies are underway to determine the relative
expression of CD164 in a large number of human
samples relative to tumor aggressiveness. These
preliminary studies may ultimately lead better targeted
therapy to prevent prostate cancer metastasis.
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